CN110193141A - A kind of tumour electric field treatment system and device - Google Patents
A kind of tumour electric field treatment system and device Download PDFInfo
- Publication number
- CN110193141A CN110193141A CN201910596328.7A CN201910596328A CN110193141A CN 110193141 A CN110193141 A CN 110193141A CN 201910596328 A CN201910596328 A CN 201910596328A CN 110193141 A CN110193141 A CN 110193141A
- Authority
- CN
- China
- Prior art keywords
- unit
- control unit
- electric field
- electrode
- electrically connected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/3603—Control systems
- A61N1/36034—Control systems specified by the stimulation parameters
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/01—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics
- C04B35/495—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics based on vanadium, niobium, tantalum, molybdenum or tungsten oxides or solid solutions thereof with other oxides, e.g. vanadates, niobates, tantalates, molybdates or tungstates
- C04B35/497—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics based on vanadium, niobium, tantalum, molybdenum or tungsten oxides or solid solutions thereof with other oxides, e.g. vanadates, niobates, tantalates, molybdates or tungstates based on solid solutions with lead oxides
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
- C04B2235/30—Constituents and secondary phases not being of a fibrous nature
- C04B2235/32—Metal oxides, mixed metal oxides, or oxide-forming salts thereof, e.g. carbonates, nitrates, (oxy)hydroxides, chlorides
- C04B2235/3205—Alkaline earth oxides or oxide forming salts thereof, e.g. beryllium oxide
- C04B2235/3206—Magnesium oxides or oxide-forming salts thereof
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
- C04B2235/30—Constituents and secondary phases not being of a fibrous nature
- C04B2235/32—Metal oxides, mixed metal oxides, or oxide-forming salts thereof, e.g. carbonates, nitrates, (oxy)hydroxides, chlorides
- C04B2235/3231—Refractory metal oxides, their mixed metal oxides, or oxide-forming salts thereof
- C04B2235/3232—Titanium oxides or titanates, e.g. rutile or anatase
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
- C04B2235/30—Constituents and secondary phases not being of a fibrous nature
- C04B2235/32—Metal oxides, mixed metal oxides, or oxide-forming salts thereof, e.g. carbonates, nitrates, (oxy)hydroxides, chlorides
- C04B2235/3231—Refractory metal oxides, their mixed metal oxides, or oxide-forming salts thereof
- C04B2235/3251—Niobium oxides, niobates, tantalum oxides, tantalates, or oxide-forming salts thereof
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/65—Aspects relating to heat treatments of ceramic bodies such as green ceramics or pre-sintered ceramics, e.g. burning, sintering or melting processes
- C04B2235/656—Aspects relating to heat treatments of ceramic bodies such as green ceramics or pre-sintered ceramics, e.g. burning, sintering or melting processes characterised by specific heating conditions during heat treatment
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/65—Aspects relating to heat treatments of ceramic bodies such as green ceramics or pre-sintered ceramics, e.g. burning, sintering or melting processes
- C04B2235/656—Aspects relating to heat treatments of ceramic bodies such as green ceramics or pre-sintered ceramics, e.g. burning, sintering or melting processes characterised by specific heating conditions during heat treatment
- C04B2235/6567—Treatment time
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Ceramic Engineering (AREA)
- Biomedical Technology (AREA)
- Manufacturing & Machinery (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Electrotherapy Devices (AREA)
Abstract
The invention belongs to medical and health care Instrument technology fields, and in particular to a kind of tumour electric field treatment system and device.The invention discloses a kind of oncotherapy electric field systems, including MCU control unit, FM signal generating unit, output voltage amplitude control unit, pulse distribution control unit, power amplification control unit, electrode output allocation unit and temperature collecting cell, voltage feedback unit, current feedback unit, power module, therapeutic electrode, display button unit.By the present invention in that pulse signal modulation frequency is in 100-300kHz, intensity in 1-2.5V/cm, electrode exports allocation unit control output signal and switched between two groups of therapeutic electrodes every 0.5-2 seconds, treatment electric field strength is set to do " tide " fluctuation, it can effectively inhibit multiple types tumour cell to increase, be suitable for the crowd of different weight, constitution.
Description
Technical field
The invention belongs to medical and health care Instrument technology fields, and in particular to a kind of tumour electric field treatment system and device.
Background technique
Oncotherapy electric field (Tumor Treating Fields, TTFields/TTF), is a kind of low-intensity intermediate frequency alternation
Electric field can prevent the formation of spindle microtubule and cell division phase organelle intracellular during certain tumour cell mitosis
Separation, the Apoptosis of induced mitogenesis phase, to realize the effect for the treatment of tumour.
Compared with traditional Cancer Treatment Regimens, TTF has the mechanism of action of innovation.Some physiology of tumour cell are special
Property, such as geometry and high frequency mitosis, make its influence vulnerable to TTF.TTF is (such as big by polar particle in the cell
Molecule and organelle) on apply directional power to destroy the Normal aggregation of tubulin.These processes may cause the object of cell membrane
Reason is destroyed and Apoptosis.And in cell mitogen latter stage, the structural form of cleavage groove will lead to the distribution of its surrounding electric field not
, while under the influence of TTF, the electric field strength at cleavage groove is significantly increased, and charge species are mobile to cleavage groove in cell, is made thin
The formation of born of the same parents' structure is interfered and even destroys, and finally can lead to cell division failure, moves towards apoptosis.
TTF is completely new tumor therapeuticing method after the treatment means such as operation, radiotherapy, chemotherapy, theoretically to all realities
Body tumor is effective.Experiment in vitro research at present is verified: TTF significantly inhibits effect to the proliferation of various tumor cell strains, such as
People's chromoma, glioma, lung cancer, prostate cancer, breast cancer, small chromoma, glioma and gland cancer are thin
Born of the same parents etc..
This field is it is desirable that can either treat known cell, additionally it is possible to the tumour cell that can not judge type
The system and device inhibited.
Summary of the invention
In order to solve the above-mentioned technical problem, the first aspect of the invention provides a kind of oncotherapy electric field system, packet
Include MCU control unit, FM signal generating unit, output voltage amplitude control unit, pulse distribution control unit, power amplification
Control unit, voltage feedback unit, current feedback unit, power module, is controlled electrode output allocation unit and temperature collecting cell
Treat electrode, display button unit.
As a kind of effective technical solution, the display button unit is electrically connected with MCU control unit；
The MCU control unit is electrically connected with FM signal generating unit, output voltage amplitude control unit respectively, described
MCU control unit is electrically connected with the output end of voltage feedback unit, current feedback unit respectively；The MCU control unit and electricity
Pole export allocation unit with temperature collecting cell is two-way is electrically connected；
The FM signal generating unit is electrically connected with pulse distribution control unit；
The output voltage amplitude control unit is electrically connected with power amplification control unit, the output voltage amplitude control
Unit is electrically connected with the output end of voltage feedback unit, current feedback unit respectively；
The pulse distribution control unit is electrically connected with power amplification control unit；
The power amplification control unit is electrically connected with electrode output allocation unit with temperature collecting cell；The power is put
Big control unit is electrically connected with the output end of voltage feedback unit, current feedback unit respectively；
The electrode output allocation unit is electrically connected with voltage feedback unit, current feedback unit respectively with temperature collecting cell
It connects；Electrode output allocation unit and temperature collecting cell with therapeutic electrode is two-way is electrically connected.
As a kind of effective technical solution, the FM signal generating unit is impulse generator, for generating pulse
Signal；The electrode output allocation unit switches output signal between two groups of therapeutic electrodes.
As a kind of effective technical solution, the modulating frequency of the pulse signal is 50-500kHz.
As a kind of effective technical solution, the modulating frequency of the pulse signal is 100-300kHz.
As a kind of effective technical solution, the intensity of the pulse signal is 1-5V/cm.
As a kind of effective technical solution, the intensity of the pulse signal is 1-2.5V/cm.
As a kind of effective technical solution, the electrode output allocation unit control output signal is in two groups of therapeutic electrodes
Between every 0.5-2 seconds switch.
As a kind of effective technical solution, the electrode output allocation unit control output signal is in two groups of therapeutic electrodes
Between every 1 second switch.
The second aspect of the present invention provides a kind of tumour electric field treatment device, including the tumour electric field treatment system.
The utility model has the advantages that by the present invention in that pulse signal modulation frequency is in 100-300kHz, intensity in 1-2.5V/cm, electricity
Pole exports allocation unit control output signal and switched between two groups of therapeutic electrodes every 0.5-2 seconds, does treatment electric field strength
" tide " fluctuation, can effectively inhibit multiple types tumour cell to increase, be suitable for the crowd of different weight, constitution.
Detailed description of the invention
Fig. 1 is the configuration diagram of tumour electric field treatment；
Fig. 2 is the structural schematic diagram of ceramic electrode；
Fig. 3 is pulse signal form schematic diagram；
Symbol description: 2-1 ceramic electrode, 2-2 centre bore.
Specific embodiment
To solve the above-mentioned problems, the present invention provides a kind of oncotherapy electric field systems, including MCU control unit, tune
Frequency signal generating unit, output voltage amplitude control unit, pulse distribution control unit, power amplification control unit, electrode are defeated
Allocation unit and temperature collecting cell, voltage feedback unit, current feedback unit, power module, therapeutic electrode, display button out
Unit.
MCU control unit: the coordinated control for each unit；
FM signal generating unit: for generating the signal of various frequencies；
Voltage feedback unit: for measuring the voltage signal of output；
Current feedback unit: for measuring the current signal of output loop；
Output voltage amplitude control unit: according to the current signal of the output voltage signal of measurement and output loop, output
The output voltage values of certain analog voltage control power amplification unit, for exporting certain electric current and voltage on the electrode
Signal；
Pulse distribution control unit: the pulse of 1 group of specific time sequence is generated for controlling power amplification list according to FM signal
The control power tube input stage of member, for generating certain frequency sine voltage signal；
Power amplification control unit acts on the input stage of power tube according to 1 group of signal that pulse distribution unit exports,
For generating the sine voltage signal of certain frequency, according to the voltage signal of the amplitude control element of output voltage, control defeated
Voltage amplitude out；
Electrode exports allocation unit and temperature collecting cell: the Time-sharing control for amplified amplitude-modulated signal is defeated to one group
Out on electrode；The temperature collecting module is thermistor, and the thermistor is located at the center opening position of therapeutic electrode.
The therapeutic electrode includes n electrode (n >=1), and pairs of Time-sharing control is used to form the amplitude modulation of continuous alternately variation
Electric field.
Display button unit: for showing current power supply type, battery capacity, operating status, type of error；Key is used
In control operating status；
Wherein, the display button unit is electrically connected with MCU control unit；
The MCU control unit is electrically connected with FM signal generating unit, output voltage amplitude control unit respectively, described
MCU control unit is electrically connected with the output end of voltage feedback unit, current feedback unit respectively；The MCU control unit and electricity
Pole export allocation unit with temperature collecting cell is two-way is electrically connected；
The FM signal generating unit is electrically connected with pulse distribution control unit；
The output voltage amplitude control unit is electrically connected with power amplification control unit, the output voltage amplitude control
Unit is electrically connected with the output end of voltage feedback unit, current feedback unit respectively；
The pulse distribution control unit is electrically connected with power amplification control unit；
The power amplification control unit is electrically connected with electrode output allocation unit with temperature collecting cell；The power is put
Big control unit is electrically connected with the output end of voltage feedback unit, current feedback unit respectively；
The electrode output allocation unit is electrically connected with voltage feedback unit, current feedback unit respectively with temperature collecting cell
It connects；Electrode output allocation unit and temperature collecting cell with therapeutic electrode is two-way is electrically connected.
The power module is external power supply/battery pack.External power supply/the battery pack is electrically connected with MCU control unit,
External power supply/battery pack is electrically connected with FM signal generating unit, external power supply/battery pack and pulse distribution control unit are electrically connected
It connects, external power supply/battery pack is electrically connected with power amplification control unit.
The working principle of the electric field treatment instrument are as follows:
(1) by the voltage signal of therapeutic electrode, MCU control unit is fed back to；By the current signal of therapeutic electrode, instead
MCU control unit of feeding feeds back to MCU control unit by the temperature signal of therapeutic electrode；
(2) MCU control unit output control instruction occurs to output voltage amplitude control unit, FM signal single respectively
Member；
(3) output voltage amplitude control unit receives the voltage and current signal of output electrode, exports certain voltage letter
Number power amplification unit is arrived, FM signal generating unit is for generating pulse signal；
(4) current signal and voltage letter in therapeutic electrode are acquired in real time by current feedback unit and voltage feedback unit
Number, the current signal and voltage signal of output are controlled, and judge whether to be more than that electric current maximum limits, alarms and disconnect output.
As an implementation, the FM signal generating unit is impulse generator, for generating pulse signal；Institute
Electrode output allocation unit is stated to switch output signal between two groups of therapeutic electrodes.
As an implementation, the modulating frequency of the pulse signal is 50-500kHz.
As a preferred embodiment, the modulating frequency of the pulse signal is 100-300kHz,
As an implementation, the intensity of the pulse signal is 1-5V/cm.
As a preferred embodiment, the intensity of the pulse signal is 1-2.5V/cm.
As a preferred embodiment, the electrode output allocation unit control output signal is in two groups of therapeutic electrodes
Between every 0.5-2 seconds switch.
Preferably, the electrode output allocation unit control output signal switched between two groups of therapeutic electrodes every 1 second.
What the modulating frequency variation of pulse signal can be enumerated are as follows: the growth or reduction of the interval 100kHz 10kHz, Ke Yilie
That lifts has: 100kHz to rise to 110kHz, and 110kHz rises to 120kHz, 120kHz again and rises to 130kHz, 130kHz to be increased again
Grow to 140kHz, 140kHz rise to again 150kHz, 150kHz rise to again 160kHz, 160kHz rise to again 170kHz,
170kHz rises to 180kHz, 180kHz again and rises to 190kHz, 190kHz again and rise to 200kHz, 200kHz again to be risen to again
210kHz, 210kHz rise to 220kHz, 220kHz again and rise to 230kHz, 230kHz again rises to 240kHz, 240kHz again
250kHz, 250kHz are risen to again rise to 260kHz, 260kHz again and rise to 270kHz, 270kHz again rise to again
280kHz, 280kHz rise to 290kHz, 290kHz again and rise to 300kHz, 300kHz is reduced to 290kHz, 290kHz again again
Be reduced to 280kHz, 280kHz be reduced to again 270kHz, 270kHz be reduced to again 260kHz, 260kHz be reduced to again 250kHz,
250kHz is reduced to 240kHz, 240kHz again and is reduced to 230kHz, 230kHz again and is reduced to 220kHz, 220kHz again to be reduced to again
210kHz, 210kHz are reduced to 200kHz, 200kHz again and are reduced to 190kHz, 190kHz again is reduced to 180kHz, 180kHz again
It it is reduced to 170kHz, 170kHz is again reduced to 160kHz, 160kHz again and is reduced to 150kHz, 150kHz again and be reduced to again
140kHz, 140kHz are reduced to 130kHz, 130kHz again and are reduced to 120kHz, 120kHz again is reduced to 110kHz, 110kHz again
It is reduced to 100kHz again.
The application tumour electric field treatment system has significant inhibiting effect to the increment of various tumor cell strains, such as pernicious black
Plain tumor, glioma, lung cancer, prostate cancer, breast cancer, gland cancer etc..Using the application tumour electric field treatment system, known
When the type of tumour cell, can targetedly it be treated by pulse signal modulation to the cell sensitive frequency, it is such as known
Cell is ovarian cancer cell, can go to be treated with the frequency of 200kHz.But certain tumour cells are unable to biopsy, ratio in practice
Such as brain tumor, we can not judge tumor cell type, be by the way that the modulating frequency of the pulse signal is arranged in the application
100-300kHz, intensity 1-2.5V/cm, and electrode output allocation unit control output signal is in two groups of therapeutic electrodes
Between every 0.5-2 seconds switch, the increment of tumour cell known to major part can be inhibited comprehensively.
According to the dielectric property of cell membrane, apply initial stage in pulse signal, electric field with pulse signal frequency and intensity increasing
Add, the bound charge inside cell membrane moves under electric field action, and cell membrane is polarized, as frequency and intensity carry out " tide "
Sample constantly changes, once per second " tide ", constantly changes the distribution of original electric field, increases polarization intensity, so that entire frequency is low
The treatment intensity of range is all strengthened；Electric field is uneven distribution especially in mitotic cell, most of electric field
Focus on connection 2 daughter cells " bridge " in, be 2 narrow cell junctions, this can all electrifications intracellular or
The molecule or other structures of polarized, such as organelle, dimer, macromolecular all pull to 2 narrow connections of daughter cell
Place, forms the dielectrophoresis phenomenon of charged particle, and formation and the Function of cell interior structure can be destroyed and be interfered to this process,
It is final to destroy tumour cell.
In one embodiment, the therapeutic electrode is made of ceramic electrode, and the therapeutic electrode uses dot matrix 3 × 3
The ceramic electrode array (such as Fig. 2) of arrangement makes therapeutic electrode can adapt to cranial anatomy shape, be close to scalp.
Further, the air dielectric between therapeutic electrode and scalp impacts encephalic electric field strength in order to prevent,
On therapeutic electrode surface, setting gel keeps electrode and scalp well to contact.
The diameter of the ceramic electrode is 18-20mm, the hole of diameter 2-4mm is arranged for placing temperature-sensitive in ceramic electrode center
Resistance.
Preferably, the diameter of the ceramic electrode is 19mm, the hole of diameter 3mm is arranged for placing heat in ceramic electrode center
Quick resistance.
In a preferred embodiment, it includes Pb that the ceramic electrode, which prepares raw material,3O4、TiO2、Nb2O5、
(MgCO3)4Mg(OH)2·5H2O。
By weight, the ceramic electrode raw material includes 66~67 parts of Pb3O4, 1.7~1.8 parts of TiO2, 22.5~24 parts
Nb2O5, 8~9 parts of (MgCO3)4Mg(OH)2·5H2O。
Preferably, by weight, the ceramic electrode raw material includes 66.41 parts of Pb3O4, 1.75 parts of TiO2, 23.17 parts
Nb2O5, 8.79 parts of (MgCO3)4Mg(OH)2·5H2O。
Applicants have discovered that a certain proportion of raw material Pb is added3O4、TiO2、Nb2O5、(MgCO3)4Mg(OH)2·5H2O, energy
The excellent ceramic electrode of enough processabilities, it is big (big which meets high dielectric constant (being greater than 20000), capacitance simultaneously
In 20nF), condition of the internal resistance less than 150 Ω, can be good at be applied to tumour electric field treatment equipment.
As a preferred embodiment, the preparation method of the ceramic electrode, comprising the following steps:
S1 is matched according to design, weighs Pb respectively3O4, TiO2, Nb2O5, (MgCO3)4Mg(OH)2·5H2O is put into ball grinder
Middle carry out ball milling, using water as dispersing agent, revolving speed 100r/min, the time 3 hours；
S2 is put into Muffle furnace after drying slurry made from step S1 and carries out pre-burning, and 900 DEG C of calcined temperature, heat preservation 2 is small
When, cooling；
Ball milling in ball grinder is added in slurry made from step S2 by S3, using water as dispersing agent, revolving speed 100r/min, and the time 2
Hour；
S4 takes poly-vinyl alcohol solution to be added in slurry made from step S3, stirs evenly；
S5 slurry made from 16t hydraulic press pressing step S4, pressure 6MPa, dwell time 6s obtain blank；
Blank is put into Muffle furnace and is sintered by S6,1200 DEG C of sintering temperature, keep the temperature 2 hours to get.
Wherein, PVA solution the preparation method comprises the following steps: 10g PVA is dissolved in 100mL deionized water.
The PVA model 1799.
The present invention is specifically described below by embodiment.It is necessarily pointed out that following embodiment is only used
In the invention will be further described, it should not be understood as limiting the scope of the invention, professional and technical personnel in the field
The some nonessential modifications and adaptations made according to the content of aforementioned present invention, still fall within protection scope of the present invention.
In addition, if without other explanations, it is raw materials used to be all commercially available.
Embodiment
Technology of the invention, which is imitated, to be illustrated to the inhibiting effect of ovarian cancer cell A2780 by research tumour electric field treatment system
Fruit.Ovarian cancer cell culture: A2780 cell culture is in containing 10% fetal calf serum, 100U/mL penicillin, 100ng/mL streptomysin
In 1640 culture mediums of 2 μ g/mL DDP, keeping incubator temperature is 37 DEG C, CO2Concentration is 5%.
The A2780 cell of logarithmic growth phase, it is 2 × 10 that concentration, which is made,5Five groups of the cell suspending liquid of a/ml, wherein often
Group cell suspending liquid is used for one embodiment (embodiment 1-5), and 1ml cell suspension is placed on to the training of 54mm in electric field experimental group
It supports and carries out electric field treatment experiment in ware, the time that test ovarian cancer cell A2780 quantity multiplication needs.
Implement the oncotherapy electric field system in 1-7: including MCU control unit, FM signal generating unit, output voltage
Amplitude control element, pulse distribution control unit, power amplification control unit, electrode output allocation unit and temperature acquisition list
Member, voltage feedback unit, current feedback unit, power module, therapeutic electrode, display button unit.
The display button unit is electrically connected with MCU control unit；
The MCU control unit is electrically connected with FM signal generating unit, output voltage amplitude control unit respectively, described
MCU control unit is electrically connected with the output end of voltage feedback unit, current feedback unit respectively；The MCU control unit and electricity
Pole export allocation unit with temperature collecting cell is two-way is electrically connected；
The FM signal generating unit is electrically connected with pulse distribution control unit；
The output voltage amplitude control unit is electrically connected with power amplification control unit, the output voltage amplitude control
Unit is electrically connected with the output end of voltage feedback unit, current feedback unit respectively；
The pulse distribution control unit is electrically connected with power amplification control unit；
The power amplification control unit is electrically connected with electrode output allocation unit with temperature collecting cell；The power is put
Big control unit is electrically connected with the output end of voltage feedback unit, current feedback unit respectively；
The electrode output allocation unit is electrically connected with voltage feedback unit, current feedback unit respectively with temperature collecting cell
It connects；Electrode output allocation unit and temperature collecting cell with therapeutic electrode is two-way is electrically connected.
The battery pack is electrically connected with MCU control unit, external power supply/battery pack and FM signal generating unit are electrically connected
It connects, external power supply/battery pack is electrically connected with pulse distribution control unit, external power supply/battery pack and power amplification control unit
Electrical connection.
Implement 1-7 in ceramic electrode the preparation method comprises the following steps:
S1 is matched according to design, weighs Pb respectively3O4, TiO2, Nb2O5, (MgCO3)4Mg(OH)2·5H2O is put into ball grinder
Middle carry out ball milling, using water as dispersing agent, revolving speed 100r/min, the time 3 hours；
S2 is put into Muffle furnace after drying slurry made from step S1 and carries out pre-burning, and 900 DEG C of calcined temperature, heat preservation 2 is small
When, cooling；
Ball milling in ball grinder is added in slurry made from step S2 by S3, using water as dispersing agent, revolving speed 100r/min, and the time 2
Hour；
S4 takes poly-vinyl alcohol solution to be added in slurry made from step S3, stirs evenly；
S5 slurry made from 16t hydraulic press pressing step S4, pressure 6MPa, dwell time 6s obtain blank；
Blank is put into Muffle furnace and is sintered by S6,1200 DEG C of sintering temperature, keep the temperature 2 hours to get.
Wherein, PVA solution the preparation method comprises the following steps: 10g PVA is dissolved in 100mL deionized water.
The PVA model 1799.
Embodiment 1
Tumour electric field treatment system is studied to the inhibiting effect of ovarian cancer cell A2780, the pulse signal frequency is
200kHz, intensity 1.5V/cm.Two groups of therapeutic electrodes, the ceramic electrode array that the therapeutic electrode uses dot matrix 3 × 3 to arrange,
By weight, the ceramic electrode raw material includes 66.41 parts of Pb3O4, 1.75 parts of TiO2, 23.17 parts of Nb2O5, 8.79 parts
(MgCO3)4Mg(OH)2·5H2O。
Show that the multiplication of ovarian cancer cell A2780 quantity needs 18.7 hours.
Embodiment 2
Tumour electric field treatment system is studied to the inhibiting effect of ovarian cancer cell A2780, the pulse signal frequency is
100-300kHz, intensity 1-2.5V/cm, the electrode output allocation unit control output signal is between two groups of therapeutic electrodes
Switched every 1 second.Two groups of therapeutic electrodes, the ceramic electrode array that the therapeutic electrode uses dot matrix 3 × 3 to arrange, by weight
Meter, the ceramic electrode raw material include 66.41 parts of Pb3O4, 1.75 parts of TiO2, 23.17 parts of Nb2O5, 8.79 parts of (MgCO3)4Mg
(OH)2·5H2O。
Show that the multiplication of ovarian cancer cell A2780 quantity needs 28.5 hours.
Embodiment 3
Tumour electric field treatment system is studied to the inhibiting effect of ovarian cancer cell A2780, the pulse signal frequency is
100-300kHz, intensity 1-2.5V/cm, the electrode output allocation unit control output signal is between two groups of therapeutic electrodes
Switched every 5 seconds.Two groups of therapeutic electrodes, the ceramic electrode array that the therapeutic electrode uses dot matrix 3 × 3 to arrange, by weight
Meter, the ceramic electrode raw material include 66.41 parts of Pb3O4, 1.75 parts of TiO2, 23.17 parts of Nb2O5, 8.79 parts of (MgCO3)4Mg
(OH)2·5H2O。
Show that the multiplication of ovarian cancer cell A2780 quantity needs 21.9 hours.
Embodiment 4
Tumour electric field treatment system is studied to the inhibiting effect of ovarian cancer cell A2780, the pulse signal frequency is
100-300kHz, intensity 1-2.5V/cm, the electrode output allocation unit control output signal is between two groups of therapeutic electrodes
Switched every 0.2 second.Two groups of therapeutic electrodes, the ceramic electrode array that the therapeutic electrode uses dot matrix 3 × 3 to arrange, by weight
Part meter, the ceramic electrode raw material include 66.41 parts of Pb3O4, 1.75 parts of TiO2, 23.17 parts of Nb2O5, 8.79 parts of (MgCO3)4Mg
(OH)2·5H2O。
Show that the multiplication of ovarian cancer cell A2780 quantity needs 22.6 hours.
Embodiment 5
Tumour electric field treatment system is studied to the inhibiting effect of ovarian cancer cell A2780, the pulse signal frequency is
200-300kHz, intensity 1-2.5V/cm, the electrode output allocation unit control output signal is between two groups of therapeutic electrodes
Switched every 5 seconds.Two groups of therapeutic electrodes, the ceramic electrode array that the therapeutic electrode uses dot matrix 3 × 3 to arrange, by weight
Meter, the ceramic electrode raw material include 66.41 parts of Pb3O4, 1.75 parts of TiO2, 23.17 parts of Nb2O5, 8.79 parts of (MgCO3)4Mg
(OH)2·5H2O。
Show that the multiplication of ovarian cancer cell A2780 quantity needs 24.3 hours.
Embodiment 6
Tumour electric field treatment system is studied to the inhibiting effect of human umbilical vein endothelial cell, the pulse signal frequency is
150kHz, intensity 1.5V/cm.Two groups of therapeutic electrodes, by weight, the ceramic electrode raw material include 66.41 parts of Pb3O4、
1.75 part TiO2, 23.17 parts of Nb2O5, 8.79 parts of (MgCO3)4Mg(OH)2·5H2O。
Human umbilical vein endothelial cell culture: A549 cell is placed in the DMEM minimal medium containing 10% fetal calf serum, 37
DEG C, 5%CO2Secondary culture is carried out in incubator；The A549 cell of logarithmic growth phase, it is 2 × 10 that concentration, which is made,5A/ml's is thin
Born of the same parents' suspension；Electric field is applied to suspension, show that the multiplication of ovarian cancer cell quantity needs 26.7 hours.
Embodiment 7
Tumour electric field treatment system is studied to the inhibiting effect of ovarian cancer cell A2780, the pulse signal frequency is
100-300kHz, intensity 1-2.5V/cm, the electrode output allocation unit control output signal is between two groups of therapeutic electrodes
Switched every 1 second.Two groups of therapeutic electrodes, the ceramic electrode array that the therapeutic electrode uses dot matrix 3 × 3 to arrange, by weight
Meter, the ceramic electrode raw material include 66.7 parts of Pb3O4, 2.3 parts of TiO2, 22.77 parts of Nb2O5, 8.31 parts of (MgCO3)4Mg
(OH)2·5H2O。
Show that the multiplication of ovarian cancer cell A2780 quantity needs 19.6 hours.
The above is only presently preferred embodiments of the present invention, is not the limitation for making other forms to invention, any
Those skilled in the art are changed or are changed to the equivalent of equivalent variations possibly also with the technology contents of the disclosure above
Embodiment, but without departing from the technical solutions of the present invention, above embodiments are made according to the technical essence of the invention
Any simple modification, equivalent variations and remodeling, still fall within the protection scope of technical solution of the present invention.
Claims (10)
1. a kind of oncotherapy electric field system, it is characterised in that: including MCU control unit, FM signal generating unit, output electricity
Press amplitude control element, pulse distribution control unit, power amplification control unit, electrode output allocation unit and temperature acquisition list
Member, voltage feedback unit, current feedback unit, power module, therapeutic electrode, display button unit.
2. oncotherapy electric field system as described in claim 1, which is characterized in that the display button unit and MCU are controlled
Unit electrical connection；
The MCU control unit is electrically connected with FM signal generating unit, output voltage amplitude control unit respectively, the MCU
Control unit is electrically connected with the output end of voltage feedback unit, current feedback unit respectively；The MCU control unit and electrode are defeated
Out allocation unit with temperature collecting cell is two-way is electrically connected；
The FM signal generating unit is electrically connected with pulse distribution control unit；
The output voltage amplitude control unit is electrically connected with power amplification control unit, the output voltage amplitude control unit
It is electrically connected respectively with the output end of voltage feedback unit, current feedback unit；
The pulse distribution control unit is electrically connected with power amplification control unit；
The power amplification control unit is electrically connected with electrode output allocation unit with temperature collecting cell；The power amplification control
Unit processed is electrically connected with the output end of voltage feedback unit, current feedback unit respectively；
The electrode output allocation unit is electrically connected with voltage feedback unit, current feedback unit respectively with temperature collecting cell；
Electrode output allocation unit and temperature collecting cell with therapeutic electrode is two-way is electrically connected.
3. oncotherapy electric field system as described in claim 1, which is characterized in that the FM signal generating unit is used to produce
Raw pulse signal；The electrode output allocation unit switches output signal between two groups of therapeutic electrodes.
4. oncotherapy electric field system as claimed in claim 3, which is characterized in that the modulating frequency of the pulse signal is
50-500kHz。
5. oncotherapy electric field system as claimed in claim 4, which is characterized in that the modulating frequency of the pulse signal is
100-300kHz。
6. oncotherapy electric field system as claimed in claim 3, which is characterized in that the intensity of the pulse signal is 1-5V/
cm。
7. oncotherapy electric field system as claimed in claim 6, which is characterized in that the intensity of the pulse signal is 1-
2.5V/cm。
8. oncotherapy electric field system as claimed in claim 3, which is characterized in that the electrode output allocation unit control is defeated
Signal switched between two groups of therapeutic electrodes every 0.5-2 seconds out.
9. oncotherapy electric field system as claimed in claim 8, which is characterized in that the electrode output allocation unit control is defeated
Signal switched between two groups of therapeutic electrodes every 1 second out.
10. a kind of tumour electric field treatment device, which is characterized in that including any one of the claim 1~9 tumour electric field treatment
System.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910596328.7A CN110193141A (en) | 2019-07-03 | 2019-07-03 | A kind of tumour electric field treatment system and device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910596328.7A CN110193141A (en) | 2019-07-03 | 2019-07-03 | A kind of tumour electric field treatment system and device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110193141A true CN110193141A (en) | 2019-09-03 |
Family
ID=67755746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910596328.7A Withdrawn CN110193141A (en) | 2019-07-03 | 2019-07-03 | A kind of tumour electric field treatment system and device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110193141A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111408045A (en) * | 2020-04-02 | 2020-07-14 | 河北普尼医疗科技有限公司 | Intermediate frequency alternating electric field treatment device for deep tumor |
| CN111420270A (en) * | 2020-04-02 | 2020-07-17 | 河北普尼医疗科技有限公司 | Periodically operated deep tumor electric field treatment device |
| CN113018682A (en) * | 2021-02-25 | 2021-06-25 | 杭州维那泰克医疗科技有限责任公司 | Cell division suppressing device, method, device, system and storage medium for controlling the same |
| CN113289247A (en) * | 2021-05-20 | 2021-08-24 | 杭州维那泰克医疗科技有限责任公司 | Electrode patch and cell division suppression device |
| CN114146308A (en) * | 2020-12-29 | 2022-03-08 | 江苏海莱新创医疗科技有限公司 | Temperature control device of electric field therapeutic apparatus and adjusting method thereof |
| CN114768091A (en) * | 2022-03-28 | 2022-07-22 | 湖南安泰康成生物科技有限公司 | Colon cancer treatment system and alternating electric field generating device for colon cancer treatment |
| CN115505524A (en) * | 2022-10-31 | 2022-12-23 | 湖南安泰康成生物科技有限公司 | Culture dish temperature self-adaptive adjusting method and device, host and storage medium |
| CN114887219B (en) * | 2022-05-19 | 2023-09-01 | 杭州赛米健康科技有限公司 | Electric field device for treating tumor |
-
2019
- 2019-07-03 CN CN201910596328.7A patent/CN110193141A/en not_active Withdrawn
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111408045A (en) * | 2020-04-02 | 2020-07-14 | 河北普尼医疗科技有限公司 | Intermediate frequency alternating electric field treatment device for deep tumor |
| CN111420270A (en) * | 2020-04-02 | 2020-07-17 | 河北普尼医疗科技有限公司 | Periodically operated deep tumor electric field treatment device |
| CN111408045B (en) * | 2020-04-02 | 2023-04-28 | 河北普尼医疗科技有限公司 | Intermediate frequency alternating electric field treatment device for deep tumor |
| CN111420270B (en) * | 2020-04-02 | 2023-04-28 | 河北普尼医疗科技有限公司 | Deep tumor electric field treatment device with periodic operation |
| CN114146308A (en) * | 2020-12-29 | 2022-03-08 | 江苏海莱新创医疗科技有限公司 | Temperature control device of electric field therapeutic apparatus and adjusting method thereof |
| CN113018682A (en) * | 2021-02-25 | 2021-06-25 | 杭州维那泰克医疗科技有限责任公司 | Cell division suppressing device, method, device, system and storage medium for controlling the same |
| CN113289247A (en) * | 2021-05-20 | 2021-08-24 | 杭州维那泰克医疗科技有限责任公司 | Electrode patch and cell division suppression device |
| CN113289247B (en) * | 2021-05-20 | 2024-06-11 | 杭州维纳安可医疗科技有限责任公司 | Electrode patch and cell division suppressing device |
| CN114768091A (en) * | 2022-03-28 | 2022-07-22 | 湖南安泰康成生物科技有限公司 | Colon cancer treatment system and alternating electric field generating device for colon cancer treatment |
| CN114887219B (en) * | 2022-05-19 | 2023-09-01 | 杭州赛米健康科技有限公司 | Electric field device for treating tumor |
| CN115505524A (en) * | 2022-10-31 | 2022-12-23 | 湖南安泰康成生物科技有限公司 | Culture dish temperature self-adaptive adjusting method and device, host and storage medium |
| CN115505524B (en) * | 2022-10-31 | 2023-11-10 | 湖南安泰康成生物科技有限公司 | Temperature self-adaptive regulation method and device for culture dish, host and storage medium |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110193141A (en) | A kind of tumour electric field treatment system and device | |
| CN106823145A (en) | A kind of device of use amplitude modulation electric field treatment tumour | |
| US7519420B2 (en) | Apparatus for selectively destroying dividing cells | |
| US7912540B2 (en) | Article of clothing for treating a tumor or the like | |
| EP3572123B1 (en) | Apparatus for treating a tumor by an electric field | |
| CN108472071A (en) | Method, system and equipment for the ablation of tissue for using pulse shape design | |
| CN110354389A (en) | A kind of equipment of alternating electric field treatment tumour | |
| Scuderi et al. | The use of high-frequency short bipolar pulses in cisplatin electrochemotherapy in vitro | |
| CN108671389A (en) | Multi-mode is wearable through cranium electric current stimulating apparatus | |
| CA3118718C (en) | Megahertz compression of nanosecond pulse bursts | |
| US20180036529A1 (en) | System and method for electroporation controlled by electrical impedance measurements | |
| CN112007277A (en) | Pulsed electromagnetic field device for breast cancer treatment | |
| CN114209978A (en) | Electric field generating device, electric field generating apparatus, and electric field control method | |
| Miklavčič et al. | Electroporation | |
| IL303111A (en) | System and methods for treating cancer cells with alternating polarity magnetic fields | |
| CN211132716U (en) | Tumor therapeutic apparatus | |
| CN209392585U (en) | A kind of electric field bringing device of selective depression specific cells growth | |
| CN210873761U (en) | Equipment for treating tumor by alternating electric field | |
| Rodamporn | Optimal parameters of electroporation for gene and tissue | |
| CN109908476B (en) | Wearable multi-mode wireless nerve stimulation system | |
| Yamamoto et al. | Consideration of pulse-width effects of nanosecond pulsed electric fields application on cancer cell | |
| CN110115803A (en) | A kind of power supply device can be used for biomedical research and auxiliary electrode Array Design | |
| Kavitha et al. | Effective electro-chemo-therapy for proliferation control of adult human mesenchymal stem cells | |
| CN116803448A (en) | Tumor electric field therapeutic instrument and control system | |
| CN105695329A (en) | Experimental device and method for high-throughput electrical-stimulation cell differentiation induction and drug controlled release |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190903 |